



OPEN

Cytotoxic naphtho- and benzofurans from an endophytic fungus *Epicoccum nigrum* Ann-B-2 associated with *Annona squamosa* fruits

Mohamed S. Elnaggar[✉], Shaimaa Fayez[✉], Alaa Anwar & Sherif S. Ebada[✉]

Chemical exploration of the total extract derived from *Epicoccum nigrum* Ann-B-2, an endophyte associated with *Annona squamosa* fruits, afforded two new metabolites, epicoccofuran A (1) and flavimycin C (2), along with four known compounds namely, epicocconigrone A (3), epicocolide B (4), epicoccone (5) and 4,5,6-trihydroxy-7-methyl-1,3-dihydroisobenzofuran (6). Structures of the isolated compounds were elucidated using extensive 1D and 2D NMR along with HR-ESI-MS. Flavimycin C (2) was isolated as an epimeric mixture of its two diastereomers 2a and 2b. The new compounds 1 and 2 displayed moderate activity against *B. subtilis*, whereas compounds (2, 3, 5, and 6) showed significant antiproliferative effects against a panel of seven different cancer cell lines with IC₅₀ values ranging from 1.3 to 12 μM.

Literally speaking, the word endophytes means "inside or within the plant" which is a broad definition extending the spectrum of plant inhabitants to bacteria, fungi, and even insects that can colonize any organ in the plant either facultative or obligatory where their symbiotic association is, in most circumstances, harmless to the host plant^{1,2}. While endophytic bacteria can reside inside or on the surface of disinfected plant tissues, endophytic fungi generally reside inside the tissues without causing any signs of overt harm to the host plant¹. Quorum sensing is a cell-to-cell communication system that allows endophytes to overcome the host immune system^{3,4}. Over the past decades, numerous benefits have been reported for endophytes including the biological control of phytopathogens⁵⁻⁷, enhancement of plant defense and growth^{2,8-10}, environmental clean-up operations¹¹, industrial purposes^{11,12}, and the production of metabolites with great biotechnological, agricultural^{13,14}, and pharmaceutical relevance^{3,9,15-17}. Fungal endophytes have been found in almost all plant families around the Globe and adapting to all climatic conditions³. They have long been a rich reservoir of pharmacologically active metabolites that served as lead structures for the development of new antimicrobial and anticancer drugs^{3,15,18-21} specially after the evolution of resistance and unresponsiveness to the current in-use chemotherapeutics^{22,23}. The genus *Epicoccum* was reported from several plant or marine organisms and is used in the biocontrol of many pathogenic fungi due to its ability to produce a vast array of secondary metabolites including polyketides^{24,25}, diketopiperazines²⁶⁻²⁸, carotenoids²⁹, siderophores³⁰, alkaloids³¹, glycosylated tetramic acid derivatives³², and depsipeptides^{33,34} with reported antimicrobial and cytotoxic effects³⁵. The widespread mitosporic ascomycete *Epicoccum nigrum* can colonize different soils and host organisms. Studies showed that *E. nigrum* had the potential to produce the commercial fluorophore "epicocconone" which is used in cell staining and gel electrophoresis³⁵. The preharvest application of *E. nigrum* showed efficiency in controlling brown rot disease in peaches^{36,37} and potato late blight in potatoes³⁸. Pigments produced from *E. nigrum* are safe and non-toxic making them of potential use in industry³⁵. Diverse compounds have been reported from *E. nigrum* specially with antimicrobial and cytotoxic activities³⁹⁻⁴³. In the course of our search for antimicrobial and antitumor compounds from plant-associated

Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt. ✉email: mohamed.s.elnaggar@pharma.asu.edu.eg; shaimaa_fayez@pharma.asu.edu.eg; sherif.elsayed@helmholtz-hzi.de; sherif_elsayed@pharma.asu.edu.eg

fungi, we report in this study the isolation and structure elucidation of two previously undescribed naphtho- and benzofuran derivatives (**1** and **2**) along with four known metabolites, epicocconigrone A (**3**)⁴⁰, epicocolide B (**4**)²⁴, epicoccone (**5**)^{44,45}, and 4,5,6-trihydroxy-7-methyl-1,3-dihydroisobenzofuran (**6**)^{45,46}, from the total extract of *Epicoccum nigrum* Ann-B-2 derived from *Annona squamosa* fruits together with their results in antimicrobial and cytotoxicity assays.

Materials and methods

General experimental procedures

Optical rotation values were determined on an Anton Paar MCP-150 polarimeter (Seelze, Germany) at room temperature in DMSO or methanol at 589 nm and 100 mm path length. The NMR data (1D and 2D) were acquired in DMSO-*d*₆ on a Bruker Avance III 500 spectrometer (Bremen, Germany) equipped with a 5 mm TXI cryoprobe (¹H NMR 500 MHz and ¹³C NMR 125 MHz) or Avance III 700 (Bruker, ¹H 700 MHz, ¹³C 175 MHz) spectrometers referenced to the residual solvent peak 2.50 ppm and 39.52 ppm for ¹H and ¹³C NMR, respectively. The HR-ESI-MS analysis were conducted on a maXis ESI-TOF mass spectrometer with a capillary voltage set at 4500 V and a scan range covering *m/z* 100–2500. The mass spectrometer was connected to an Agilent 1200 HPLC–UV system (Santa Clara, CA, USA) scanning over 200–400 nm. Molecular formulas of the indicated compounds were calculated using the Smart Formula algorithm of the Compass Data Analysis software (Bruker, version 4.4). Analytical HPLC was performed using a Dionex UltiMate 3000 UHPLC (Thermo Fisher Scientific Inc.) equipped with a C18 Acquity UPLC BEH column (2.1 × 50 mm, 1.7 μm, Waters, Milford, USA) and the UV/Vis detections recorded at 190–600 nm. The following gradient was implemented as a mobile phase: 5% B for 0.5 min reaching 100% B in 19.5 min with a flow rate at 0.6 ml/min where solvent A is water + 0.1% formic acid (v/v) and solvent B is acetonitrile + 0.1% formic acid (v/v). The HPLC solvents were purchased from Merck Co. (Darmstadt, Germany).

Fungal material

Epicoccum nigrum Ann-B-2 strain was isolated and purified from the inner tissues of the edible fruit *Annona squamosa*. *Annona* fruits were collected from different locations within Cairo Governorate, Egypt, in February 2021, and was thankfully authenticated by taxonomist Dr. Terraize Demian. The collection was complied with the IUCN Policy Statement on Research Involving Species at Risk of extinction and collection requirements and were carefully followed in the conduct of this research to comply with institutional, national, and international guidelines and legislation. To isolate the fungal strain, the edible fruit was rinsed with distilled water then surface sterilization was performed using 70% ethanol for 60 s. Small pieces from the innermost tissues of the edible fruit were aseptically cut using sterilized blade and pressed onto malt extract agar plate (15 g/L malt extract, 15 g/L agar, 0.2 g/L chloramphenicol to suppress bacterial growth, pH adjusted to 7.4–7.8 using 10% NaOH if needed). After incubation at 25°C, inspection for the fungal growth was followed in which the fungal strain under investigation was found to grow out from the fruit tissues. Pure fungal strains were grown by repeated re-inoculation on fresh culture media.

Fermentation and extraction

Fermentation of fungal strain was performed on solid rice culture media (100 g rice in 110 mL distilled water, autoclaved for 20 min at 121 °C) in 1L Erlenmeyer flask (12 flasks were used). The culture was incubated for 6 weeks at 25 °C under static conditions. After the fermentation period, fungal biomass were extracted successively with ethyl acetate (3 × 600 mL per flask), combined, and concentrated under vacuum where the residue was defatted between *n*-hexane and 90% aqueous methanol to give a total of 6.0 g dark brown extract by evaporating the aqueous phase under reduced pressure.

DNA extraction and PCR analysis

DNA amplification and sequencing of the ITS region was implemented using a similar protocol as previously described by Kjer et al.⁴⁷. The sequence was submitted to GenBank for comparison leading to a 99% identity to *Epicoccum nigrum* Ann-B-2 with an accession code OQ780784.

Isolation of compounds 1–6

The defatted methanol-soluble extract (6.0 g) was fractionated on silica using vacuum liquid chromatography by implementing a gradient system composed of *n*-heptane:dichloromethane (10:0, 7:3, 3:7, and 0:10) then another gradient formed from dichloromethane:methanol at 10:0, 9:1, 3:2, and 0:10. After pooling similar fractions based on their LCMS dereplication, a total of eight fractions (E₁–E₈) were obtained. Fraction E₆ (940 mg, eluted from DCM:MeOH (9:1)) revealed unprecedented masses in LCMS and was further fractionated on 50 g of Diaion HP20 using a gradient system of water:acetonitrile (10:0, 7:3, 1:1, 3:7, and 0:10) yielding five subfractions (E₆H₁–E₆H₅). Subfraction E₆H₂ (80 mg) was purified on a preparative HPLC (PLC 2020; Gilson) using Gemini C₁₈ (250 mm × 21 mm, 10 μm: Phenomenex) column, solvent A (deionized H₂O + 0.1% TFA (v/v)) and solvent B (acetonitrile + 0.1% TFA (v/v)); a flow rate of 15 mL/min; and the UV detection at 210, 254 and 280 nm; gradient: 5 min holding at 5% B, increasing B to 25% in 15 min, increasing B to 100% B in 25 min, and then holding at 100% B for 10 min) to yield compounds **6** (2.5 mg, *t*_R = 17 min) and **5** (1.5 mg, *t*_R = 22 min). Using the same preparative HPLC conditions, subfraction E₆H₅ (190 mg) was purified to afford compounds **2** (2.0 mg, *t*_R = 27 min), **1** (2.0 mg, *t*_R = 28 min), **3** (3.0 mg, *t*_R = 29 min), and **4** (3.0 mg, *t*_R = 31 min).

Epicocofuran A (1)

Off-white amorphous powder; UV (MeOH) λ_{\max} 203, 222, 308, and 437 nm; ^1H and ^{13}C NMR see Table 1; in LR-ESI-MS m/z 291.0 and at m/z 289.0; HR-ESI-MS m/z 291.0859 $[\text{M} + \text{H}]^+$ (calcd. $\text{C}_{15}\text{H}_{15}\text{O}_6^+$; 291.0858).

Flavimycin C (2)

Pale yellow powder; $[\alpha]_D^{20} +2.1$ (c 0.2, DMSO); UV (MeOH) λ_{\max} 210 and 270 nm; ^1H and ^{13}C NMR see Table 2; in LRESIMS m/z 361.0 and m/z 359.0; HR-ESI-MS m/z 361.0917 $[\text{M} - \text{CH}_3\text{OH} + \text{H}]^+$ (calcd. $\text{C}_{18}\text{H}_{17}\text{O}_8^+$; 361.0919) and m/z 359.0771 $[\text{M} - \text{CH}_3\text{OH} - \text{H}]^-$ (calcd. $\text{C}_{18}\text{H}_{15}\text{O}_8^-$; 359.0768).

Pos	$\delta_{\text{C}},^{\text{a,c}}$ type	$\delta_{\text{H}}^{\text{b}}$ (J in Hz)	HMBC ^b	ROESY ^b
1	78.2, CH ₂	5.13 (t, 3.1, 2H)	3w, ^d 4w, ^d 12w, ^d 13w ^d	H ₃ -15
3	75.5, CH ₂	4.97 (t, 3.1, 2H)	1w, ^d 4w, ^d 5w, ^d 13w ^d	H ₃ -14
4	134.5, C			
5	119.9, C			
6	151.0, C			
7	132.7, C			
8	149.0, C	14.89 (brs, OH)		
9	116.8, C			
10	150.7, C			
11	114.2, C			
12	127.3, C			
13	133.0, C			
14	14.9, CH ₃	2.09 (s, 3H)	4, 5, 6	H ₂ -3
15	15.2, CH ₃	2.19 (s, 3H)	10, 11, 12	H ₂ -1
16	183.4, CO			

Table 1. 1D (^1H and ^{13}C) and 2D (HMBC and ROESY) NMR data of epicocofuran A (1). Measured in DMSO- d_6 ^aat 125 MHz / ^bat 500 MHz. ^cAssigned based on HMBC and HSQC spectra. ^d”w” denotes a weak correlation.

Pos	2a		2b	
	$\delta_{\text{C}},^{\text{a,c}}$ type	$\delta_{\text{H}}^{\text{b}}$ (J in Hz)	$\delta_{\text{C}},^{\text{a,c}}$ type	$\delta_{\text{H}}^{\text{b}}$ (J in Hz)
1	108.0, CH	6.18 (s, 1H)	106.6, CH	6.24 (d, 2.2, 1H)
3	84.5, CH	5.10 (d, 8.3, 1H)	85.0, CH	5.35, (dd, 7.0, 2.2, 1H)
4	116.6, C		116.9, C	
5	137.7, C		137.6, C	
6	134.3, C		134.2, C	
7	145.0, C		144.9, C	
8	110.8, C		110.5, C	
9	125.8, C		126.2, C	
10	11.1, CH ₃	2.00 (s, 3H)	11.1, CH ₃	1.99 (s, 3H)
11	54.2, CH ₃	3.37 (s, 3H)	52.0, CH ₃	3.12 (s, 3H)
1'	72.8, CH ₂	α 4.93 (d, 11.0, 1H)	72.9, CH ₂	α 4.96 (d, 10.4, 1H)
		β 5.10 (dd, 11.0, 2.5, 1H)		β 5.22 (dd, 10.4, 5.1, 1H)
3'	87.2, CH	5.20 (m, overlapped, 1H)	86.4, CH	5.21 (m, overlapped, 1H)
4'	114.5, C		114.8, C	
5'	138.5, C		138.2, C	
6'	132.3, C		132.5, C	
7'	144.8, C		145.0, C	
8'	108.2, C		108.4, C	
9'	128.5, C		128.3, C	
10'	12.1, CH ₃	1.92 (s, 3H)	12.1, CH ₃	1.94 (s, 3H)

Table 2. 1D (^1H and ^{13}C) NMR data of flavimycin C (2a and 2b). Measured in DMSO- d_6 ^aat 175 MHz / ^bat 700 MHz. ^cAssignment confirmed by HMBC and HSQC spectra.

Antimicrobial assay

A panel of Gram-positive and Gram-negative bacteria along with fungal strains (Table 3), namely; (bacteria: *Staphylococcus aureus* [DSM 346], *Mycobacterium smegmatis* [ATCC 700084] and *Bacillus subtilis* [DSM 10] and fungi: *Mucor hiemalis* [DSM 2656], *Candida albicans* [DSM 1665] and *Rhodotorula glutinis* [DSM 10134]) were used to evaluate the minimum inhibitory concentrations (MIC) of the isolated compounds 1–6 using a 96-well plate serial dilution assay over a concentration range from 67 to 0.5 µg/mL as described in our previous work^{47,48}.

Cytotoxicity assay

In vitro cytotoxicity studies (data expressed in the form of IC₅₀ values) were performed over a concentration range between 1 and 37 µg/mL on a panel of seven cancer cell lines including human endocervical adenocarcinoma (KB3.1), mouse fibroblasts (L929), lung cancer (A549), squamous cancer (A431), prostate cancer (PC-3), breast cancer (MCF-7), and ovary cancer (SK-OV-3) using the MTT assay as previously reported⁴⁹.

Results and discussion

In this study, *Epicoccum nigrum* Ann-B-2 fungus was isolated as an endophyte associated with *A. squamosa* fruits. The fungus was fermented on rice medium over four weeks at 25 °C under static conditions then extracted with ethyl acetate. The total extract was concentrated and fractionated on VLC (vacuum liquid chromatography using silica gel as a stationary phase) to yield six compounds (Fig. 1), two of them (1 and 2) were recognized as previously undescribed natural products.

Compound 1 was isolated as an off-white amorphous powder with UV absorption maxima (λ_{\max}) at 203, 222, 308, and 437 nm. The molecular formula of 1 was established as C₁₅H₁₄O₆ based on its HR-ESI-MS that revealed a protonated molecule at m/z 291.0859 [M + H]⁺ (calculated 291.0858) indicating nine degrees of unsaturation. The ¹³C NMR data (Table 1) and HSQC spectrum (Fig. S6) of 1 revealed fifteen carbon resonances distinguished into eleven unprotonated carbons including one carboxycarbonyl carbon at δ_c 183.4, three oxygenated olefinic carbons (δ_c 151.0, 150.7, and 149.0) and seven olefinic carbons (δ_c 134.5, 133.0, 132.7, 127.3, 119.9, 116.8, and

Tested organism	MIC (µg/ml)						Standard*
	1	2	3	4	5	6	
<i>Staphylococcus aureus</i>	>67	>67	>67	>67	>67	>67	0.21 ^G
<i>Mycobacterium smegmatis</i>	>67	>67	>67	>67	>67	>67	1.7 ^K
<i>Bacillus subtilis</i>	33.3	33.3	66.6	66.6	>67	>67	16.6 ^O
<i>Mucor hiemalis</i>	>67	>67	>67	>67	>67	>67	2.1 ^N
<i>Candida albicans</i>	>67	>67	>67	>67	>67	>67	2.1 ^N
<i>Rhodotorula glutinis</i>	>67	>67	>67	>67	>67	>67	2.1 ^N

Table 3. The minimum inhibitory concentrations (MIC) of compounds 1–6. ^GGentamycin 1 mg/mL, ^KKanamycin 1 mg/mL, ^OOxytetracycline 1 mg/mL, ^NNystatin 10 mg/mL.




Figure 1. Chemical structures of 1–6.

114.2) together with two deshielded oxymethylene carbons (δ_c 78.2 and 75.5) suggested to form a tetrahydrofuran ring and two aromatic methyl groups (δ_c 15.2 and 14.9).

From the ^{13}C NMR data of **1**, it was deduced to possess a tricyclic structure including one tetrahydrofuran ring and two fused aromatic rings as a naphthalene moiety comprising five double bonds interpreting eight degrees of unsaturation alongside with the carboxycarbonyl group. The ^1H NMR data and HSQC spectrum of **1** (Table 1, Fig. S6) supported its suggested structural features by exhibiting two aromatic methyl singlets at δ_H 2.09 (Me-14; δ_C 14.9) and at δ_H 2.19 (Me-15; δ_C 15.2). The HMBC of **1** (Fig. 2) disclosed key correlations from oxymethylene protons at δ_H 5.13 (H₂-1) and δ_H 4.97 (H₂-3) to both quaternary olefinic carbon atoms at δ_C 134.5 (C-4) and δ_C 133.0 (C-13) ppm confirming their existence as a tetrahydrofuran ring directly fused to an aromatic ring.

The two aromatic methyl groups (Me-14 and Me-15) were situated at C-11 and C-5 of the naphthalene ring based on the ROESY spectrum (Fig. 2) exhibiting key ROE correlations to H₂-3 and H₂-1, respectively, together with the key HMBC correlations from Me-14 to C-4 and from Me-15 to C-10 (δ_C 150.7) and C-12 (δ_C 127.3). Based on the proposed structural characteristics and by searching the reported literature, compound **1** was found to be related to unusual dibenzofurans, preussifurans A-B, previously reported as antimalarial and moderate anti-proliferative fungal metabolites from an endophytic fungus *Preussia* sp. isolated from the Cameronian medicinal plant *Enantia chlorantha* Oliv.⁵⁰ However, the depicted structure of **1** (Fig. 1) revealed a tetrahydrofuran ring fused with a naphthalene moiety rather than being a dibenzofuran scaffold. Accordingly and to the best of our knowledge, compound **1** was identified as the first report of this naphthofuranoid skeleton in natural products and hence was given the trivial name epicoccofuran A.

Compound **2** was purified as a pale-yellow powder that revealed UV absorption maxima (λ_{max}) at 210 and 270 nm. Its molecular formula was determined to be $\text{C}_{19}\text{H}_{20}\text{O}_9$ indicating ten degrees of unsaturation based on HR-ESI-MS, ^1H and ^{13}C NMR data (Table 2, Figs. S9–S11). The ^1H and ^{13}C NMR spectra of **2** were recorded in DMSO- d_6 and unveiled two sets of corresponding peaks in a ratio of 1:1 suggesting that **2** is an equal mixture of two epimers, **2a** and **2b**. Each of the two epimers comprised a singlet oxygenated methyl group at δ_H 3.37 and at δ_H 3.12 ppm that were correlated by HSQC to the two carbon resonances at δ_C 54.2 and 52.0 ppm, respectively. A literature search of **2** revealed its close resemblance to flavimycins A and B, previously reported from a soil-derived fungus *Aspergillus flavipes* by Kwon et al.⁵¹ By comparing the 1D and 2D NMR data (Table 2, Figs. 3 and S10–S14) of the two epimers **2a** and **2b** with those reported for flavimycin B⁵¹, it can be unambiguously determined that both epimers **2a** and **2b** feature its identical building units namely, 1,5,6,7-tetrahydroxy-8-methyl-1,3-dihydroisobenzofuran and 5,6,7-trihydroxy-8-methyl-1,3-dihydroisobenzofuran with a sole structural difference in the former through the presence of a methoxy group replacing the hydroxyl group at C-1. The methoxy groups were assigned at C-1 of the furan ring in each epimer as indicated by their HMBC correlations (Fig. 3) to two acetal carbon atoms resonating at δ_C 108.0 and δ_C 106.6 for the two epimers **2a** and **2b**, respectively.

The connection between the two isobenzofurans was established to be C3-C3' as evidenced by the HMBC correlations from H-3 to C-4' and C-5' and from H-3' to C-4. Two aromatic methyl groups assigned as Me-10' at δ_H 1.92 and δ_H 1.94 disclosed key ROE correlations in ROESY spectrum (Fig. 3) to diastereotopic hydroxymethylene




Figure 2. Key COSY, HMBC, and ROESY correlations of epicoccofuran A (**1**).




Figure 3. Key COSY, HMBC, and ROE correlations of flavimycin C (**2a** and **2b**).

Cancer cell line	IC ₅₀ (μM)						Epothilone B (nM)
	1	2	3	4	5	6	
KB3.1	16	7.8	2.7	21	6.1	3.4	0.17
L929	12	6.7	14	19	7.5	2.8	0.65
A549	n.t. ^a	9.2	10	n.t. ^a	6.8	6.3	0.05
A431	n.t. ^a	8.2	7.8	n.t. ^a	7.3	7.3	0.06
PC-3	n.t. ^a	>100	8.0	n.t. ^a	8.0	>100	0.09
MCF-7	n.t. ^a	2.7	2.4	n.t. ^a	3.8	1.3	0.07
SKOV-3	n.t. ^a	17	12	n.t. ^a	8.2	7.8	0.09

Table 4. In vitro cytotoxicity assay results of compounds 1–6. ^an.t.: “not tested”.

proton pairs ascribed to H₂-1' at δ_H 4.93/δ_H 5.10 (δ_c 72.8) and at δ_H 4.96/δ_H 5.22 (δ_c 72.8) in **2a** and **2b**, respectively, indicating their positions to be at C-8' in each epimer.

The vicinal coupling ($J = 8.3$ and 7.0 Hz) between the two oxygenated methine protons at C-3 and C-3' in **2a** and **2b**, respectively, suggested that both rings should be *trans*-configured. The relative configuration of the two methine protons at C-1 and C-3 in **2a** and **2b** were distinguished based on their ROE correlations where H-1 correlated to H-3 (in **2a**) and H-3' (in **2b**) hinting at *cis* and *trans* configurations, respectively. Therefore, compound **2** was identified as a mixture of two epimers **2a/2b** and it was trivially named flavimycin C.

Among the tested strains, compounds **1** and **2** displayed moderate antimicrobial activities against *Bacillus subtilis* (Table 3), however they showed no potential activity against the remaining strains. Their potency against *Bacillus* was almost half that of the standard oxytetracycline. For the cytotoxicity assessment, compounds **2** and **6** displayed the highest potency with significant inhibition to the proliferation of almost all cancer cell lines except for PC-3 (prostate cancer) which was insensitive (Table 4). Compounds **3** and **5** were likewise active against all tested cell lines, whereas compounds **1** and **4** showed weak anticancer activity.

Conclusion

Epicoccum species produce diverse bioactive secondary metabolites, a reason for their common use as biocontrol agents against several phytopathogens. Systematic LC–MS-guided investigations for the culture extract and purified fractions of *E. nigrum* isolated from *Annona squamosa* plant resulted in the identification and full characterization of two new polyketides, namely epicocofuran A (**1**) and flavimycin C (**2**). The latter was isolated as a diastereomeric mixture, along with four other known polyketides (**3–6**). Epicocofuran A (**1**) and flavimycin C (**2**) displayed moderate activity against *B. subtilis* while flavimycin C (**2**), epicocconigrone A (**3**), epicoccone (**5**), and 4,5,6-trihydroxy-7-methyl-1,3-dihydroisobenzofuran (**6**) showed promising anticancer activities against seven tested cancer cell lines with the breast cancer cells being the most susceptible suggesting the use of these compounds (or their derivatives) as promising molecules for the development of anticancer therapeutics.

Data availability

Data are available upon request from the first author, Mohamed S. Elnaggar.

Received: 11 November 2023; Accepted: 21 February 2024

Published online: 28 February 2024

References

- Schulz, B. & Boyle, C. in *Microbial Root Endophytes* (eds Barbara J. E. Schulz, Christine J. C. Boyle, & Thomas N. Sieber) 1–13 (Springer Berlin Heidelberg, 2006).
- Dini-Andreote, F. Endophytes: The second layer of plant defense. *Trends Plant Sci.* **25**, 319–322. <https://doi.org/10.1016/j.tplants.2020.01.007> (2020).
- Martinez-Klimova, E., Rodríguez-Peña, K. & Sánchez, S. Endophytes as sources of antibiotics. *Biochem. Pharmacol.* **134**, 1–17. <https://doi.org/10.1016/j.bcp.2016.10.010> (2017).
- Shastri, R. P. & Rai, V. R. in *Endophytes: Biology and Biotechnology: Volume 1* (ed Dinesh K. Maheshwari) 41–57 (Springer International Publishing, 2017).
- Fontana, D. C. *et al.* Endophytic fungi: Biological control and induced resistance to phytopathogens and abiotic stresses. *Pathogens (Basel, Switzerland)* **10**, 570. <https://doi.org/10.3390/pathogens10050570> (2021).
- Backman, P. A. & Sikora, R. A. Endophytes: An emerging tool for biological control. *Biol. Control* **46**, 1–3. <https://doi.org/10.1016/j.biocontrol.2008.03.009> (2008).
- De Silva, N. I., Brooks, S., Lumyong, S. & Hyde, K. D. Use of endophytes as biocontrol agents. *Fungal Biol. Rev.* **33**, 133–148. <https://doi.org/10.1016/j.fbr.2018.10.001> (2019).
- Fadji, A. E. & Babalola, O. O. Exploring the potentialities of beneficial endophytes for improved plant growth. *Saudi J. Biol. Sci.* **27**, 3622–3633. <https://doi.org/10.1016/j.sjbs.2020.08.002> (2020).
- Deka, D., Tayung, K. & Jha, D. K. in *Endophytes: Biology and Biotechnology: Volume 1* (ed Dinesh K. Maheshwari) 59–98 (Springer International Publishing, 2017).
- Mengistu, A. A. Endophytes: Colonization, behaviour, and their role in defense mechanism. *Int. J. Microbiol.* **2020**, 6927219. <https://doi.org/10.1155/2020/6927219> (2020).
- Ryan, R. P., Germaine, K., Franks, A., Ryan, D. J. & Dowling, D. N. Bacterial endophytes: Recent developments and applications. *FEMS Microbiol. Lett.* **278**, 1–9. <https://doi.org/10.1111/j.1574-6968.2007.00918.x> (2008).
- Strobel, G. Harnessing endophytes for industrial microbiology. *Curr. Opin. Microbiol.* **9**, 240–244. <https://doi.org/10.1016/j.mib.2006.04.001> (2006).

13. Araujo, R., Kaewkla, O. & Franco, C. M. M. in *Endophytes: Biology and Biotechnology: Volume 1* (ed Dinesh K. Maheshwari) 171–191 (Springer International Publishing, 2017).
14. Dheeman, S., Maheshwari, D. K. & Baliyan, N. in *Endophytes: Biology and Biotechnology: Volume 1* (ed Dinesh K. Maheshwari) 193–231 (Springer International Publishing, 2017).
15. Yu, H. *et al.* Recent developments and future prospects of antimicrobial metabolites produced by endophytes. *Microbiol. Res.* **165**, 437–449. <https://doi.org/10.1016/j.micres.2009.11.009> (2010).
16. Suryanarayanan, T. S. *et al.* Fungal endophytes and bioprospecting. *Fungal Biol. Rev.* **23**, 9–19. <https://doi.org/10.1016/j.fbr.2009.07.001> (2009).
17. Skinder, B. M., Ganai, B. A. & Wani, A. H. in *Phytomedicine* (eds. Rouf Ahmad Bhat, Khalid Rehman Hakeem, & Moonisa Aslam Dervash) 427–460 (Academic Press, 2021).
18. Ancheeva, E., Daletos, G. & Proksch, P. Bioactive secondary metabolites from endophytic fungi. *Curr. Med. Chem.* **27**, 1836–1854. <https://doi.org/10.2174/0929867326666190916144709> (2020).
19. Singh, A., Singh, D. K., Kharwar, R. N., White, J. F. & Gond, S. K. Fungal endophytes as efficient sources of plant-derived bioactive compounds and their prospective applications in natural product drug discovery: Insights, avenues, and challenges. *Microorganisms* **9**, 197. <https://doi.org/10.3390/microorganisms9010197> (2021).
20. Gupta, J. & Sharma, S. in *New and Future Developments in Microbial Biotechnology and Bioengineering* (eds. Joginder Singh & Praveen Gehlot) 39–49 (Elsevier, 2020).
21. Sandhu, S. S., Kumar, S., Aharwal, R. P. & Nozawa, M. in *Endophytes: Biology and Biotechnology: Volume 1* (ed Dinesh K. Maheshwari) 303–331 (Springer International Publishing, 2017).
22. Tanwar, J., Das, S., Fatima, Z. & Hameed, S. Multidrug resistance: An emerging crisis. *Interdiscip. Perspect. Infect. Dis.* **2014**, 541340. <https://doi.org/10.1155/2014/541340> (2014).
23. Kumar, S., Kushwaha, P. P. & Gupta, S. Emerging targets in cancer drug resistance. *Cancer Drug Resist. (Alhambra, Calif.)* **2**, 161–177. <https://doi.org/10.20517/cdr.2018.27> (2019).
24. Talontsi, F. M., Dittrich, B., Schüffler, A., Sun, H. & Laatsch, H. Epicoccolides: antimicrobial and antifungal polyketides from an endophytic fungus *Epicoccum* sp. Associated with *Theobroma cacao*. *Eur. J. Org. Chem.* **2013**, 3174–3180. <https://doi.org/10.1002/ejoc.201300146> (2013).
25. Chang, C.-C. *et al.* Bioactive polyketides from the pathogenic fungus of *Epicoccum sorghinum*. *Planta* **253**, 116. <https://doi.org/10.1007/s00425-021-03635-y> (2021).
26. Guo, H. *et al.* Diketopiperazines from the cordyceps-colonizing fungus *Epicoccum nigrum*. *J. Nat. Prod.* **72**, 2115–2119. <https://doi.org/10.1021/np900654a> (2009).
27. Chi, L.-P., Li, X.-M., Li, L., Li, X. & Wang, B.-G. Cytotoxic thiodiketopiperazine derivatives from the deep sea-derived fungus *Epicoccum nigrum* SD-388. *Mar. Drugs* **18**, 160 (2020).
28. Wang, J.-M. *et al.* Thiodiketopiperazines produced by the endophytic fungus *Epicoccum nigrum*. *J. Nat. Prod.* **73**, 1240–1249. <https://doi.org/10.1021/np1000895> (2010).
29. Kaur, S., Panesar, P. S., Gurumayum, S., Rasane, P. & Kumar, V. Optimization of carotenoid pigment Extraction from *Epicoccum nigrum* fermented wheat bran. *Ind. Biotechnol.* **17**, 100–104. <https://doi.org/10.1089/ind.2020.0005> (2021).
30. Renshaw, J. C. *et al.* Fungal siderophores: Structures, functions and applications. *Mycol. Res.* **106**, 1123–1142. <https://doi.org/10.1017/S0953756202006548> (2002).
31. Harwoko, H. *et al.* Azacoccones F-H, new flavipin-derived alkaloids from an endophytic fungus *Epicoccum nigrum* MK214079. *Fitoterapia* **146**, 104698. <https://doi.org/10.1016/j.fitote.2020.104698> (2020).
32. Kemami Wangun, H. V. & Hertweck, C. Epicoccarines A, B and epiyridone: tetramic acids and pyridone alkaloids from an *Epicoccum* sp. Associated with the tree fungus *Pholiota squarrosa*. *Org. Biomol. Chem.* **5**, 1702–1705. <https://doi.org/10.1039/B702378B> (2007).
33. Blunt, J. W., Copp, B. R., Munro, M. H. G., Northcote, P. T. & Prinsep, M. R. Marine natural products. *Nat. Prod. Rep.* **22**, 15–61. <https://doi.org/10.1039/B415080P> (2005).
34. Rana, K. L. *et al.* in *Microbial Endophytes* (eds Ajay Kumar & Radhakrishnan E.K) 273–305 (Woodhead Publishing, 2020).
35. Elkhateeb, W. & Daba, G. *Epicoccum* species as potent factories for the production of compounds of industrial, medical, and biological control applications. *J. Sci. Res.* **14**, 1–5. <https://doi.org/10.26717/BJSTR.2019.14.002541> (2019).
36. Larena, I. *et al.* Biological control of postharvest brown rot (*Monilinia* spp.) of peaches by field applications of *Epicoccum nigrum*. *Biological Control* **32**, 305–310. doi:<https://doi.org/10.1016/j.biocontrol.2004.10.010> (2005).
37. De Cal, A. *et al.* Population dynamics of *Epicoccum nigrum*, a biocontrol agent against brown rot in stone fruit. *J. Appl. Microbiol.* **106**, 592–605. <https://doi.org/10.1111/j.1365-2672.2008.04030.x> (2009).
38. Li, Y. *et al.* The inhibitory effect of *Epicoccum nigrum* strain XF1 against *Phytophthora infestans*. *Biol. Control* **67**, 462–468. <https://doi.org/10.1016/j.biocontrol.2013.09.007> (2013).
39. Dzoymov, J. P. *et al.* Cytotoxicity, antioxidant and antibacterial activity of four compounds produced by an endophytic fungus *Epicoccum nigrum* associated with *Entada abyssinica*. *Rev. Brasil. Farmacog.* **27**, 251–253. <https://doi.org/10.1016/j.bjp.2016.08.011> (2017).
40. El Amrani, M. *et al.* Protein kinase and HDAC inhibitors from the endophytic fungus *Epicoccum nigrum*. *J. Nat. Prod.* **77**, 49–56. <https://doi.org/10.1021/np4005745> (2014).
41. da Silva Araújo, F. D. *et al.* Epicolactone—Natural product isolated from the sugarcane endophytic fungus *Epicoccum nigrum*. *Eur. J. Org. Chem.* **2012**, 5225–5230. <https://doi.org/10.1002/ejoc.201200757> (2012).
42. Fávoro, L. C., Sebastianes, F. L. & Araújo, W. L. *Epicoccum nigrum* P16, a sugarcane endophyte, produces antifungal compounds and induces root growth. *PLoS One* **7**, e36826. <https://doi.org/10.1371/journal.pone.0036826> (2012).
43. Qader, M. M. *et al.* Antimicrobial and antibiofilm activities of the fungal metabolites isolated from the marine endophytes *Epicoccum nigrum* M13 and *Alternaria alternata* 13A. *Mar. Drugs* **19**, 232 (2021).
44. Abdel-Lateff, A., Fisch, K. M., Wright, A. D. & König, G. M. A new antioxidant isobenzofuranone derivative from the algalicous marine fungus *Epicoccum* sp. *Planta Med.* **69**, 831–834. <https://doi.org/10.1055/s-2003-43209> (2003).
45. Braga, R. M., Padilla, G. & Araújo, W. L. The biotechnological potential of *Epicoccum* spp.: Diversity of secondary metabolites. *Crit. Rev. Microbiol.* **44**, 759–778. <https://doi.org/10.1080/1040841X.2018.1514364> (2018).
46. Ishikawa, Y. I., Ito, T. & Lee, K. H. Inhibition of sardine fish lipoxygenase by a new antioxidant from *Aspergillus terreus*. *J. Jpn. Oil Chem. Soc.* **45**, 1321–1325 (1996).
47. Hassan, K. *et al.* Meroterpenoids possibly produced by a bacterial endosymbiont of the tropical basidiomycete *Echinochaete brachypora*. *Biomolecules* **12**, 755 (2022).
48. Chepkirui, C., Richter, C., Matasyoh, J. C. & Stadler, M. Monochlorinated calocerins A-D and 9-oxostrobilurin derivatives from the basidiomycete *Favolaschia calocera*. *Phytochemistry* **132**, 95–101. <https://doi.org/10.1016/j.phytochem.2016.10.001> (2016).
49. Kemkuignou, B. M., Moussa, A. Y., Decock, C. & Stadler, M. Terpenoids and meroterpenoids from cultures of two grass-associated species of *Amyloporus* (Basidiomycota). *J. Nat. Prod.* **85**, 846–856. <https://doi.org/10.1021/acs.jnatprod.1c00975> (2022).
50. Talontsi, F. M., Lamshöft, M., Douanla-Meli, C., Kouam, S. F. & Spittler, M. Antiplasmodial and Cytotoxic Dibenzofurans from *Preussia* sp. harboured in *Enantia chlorantha* Oliv. *Fitoterapia* **93**, 233–238. <https://doi.org/10.1016/j.fitote.2014.01.003> (2014).
51. Kwon, Y. J., Sohn, M. J., Kim, C. J., Koshino, H. & Kim, W. G. Flavimycins A and B, dimeric 1,3-dihydroisobenzofurans with peptide deformylase inhibitory activity from *Aspergillus flavipes*. *J. Nat. Prod.* **75**, 271–274. <https://doi.org/10.1021/np200720v> (2012).

Acknowledgements

All authors cordially thank the research team of Microbial Drugs Department at Helmholtz Center for Infection Research, Braunschweig, Germany, for generously hosting analytical and biological experiments. This study is dedicated to Professor Peter Proksch's 70th Birthday Anniversary as an appreciation for his overwhelming contribution to the field of Natural Products Chemistry over decades.

Author contributions

Conceptualization: M.S.S., S.S.E.; Strain isolation and characterization: S.F., A.A.; Methodology and investigation: M.S.S., S.S.E.; Data curation and Interpretation: M.S.S., S.S.E.; Writing—original draft preparation: M.S.S., S.F., S.S.E.; writing—review and editing: All authors read and approved the final manuscript.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-024-55168-5>.

Correspondence and requests for materials should be addressed to M.S.E., S.F. or S.S.E.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024